Navigation Links
Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share
Date:12/10/2010

reviously announced tender offer for $4.25 per share until 12:00 Midnight, New York City time, on December 17, 2010, unless the offer is further extended.  The tender offer was previously scheduled to expire at 12:00 Midnight, New York City time, on December 10, 2010.  All other material terms and conditions of the tender offer remain unchanged.

Previously, on September 15, 2010, Ramius announced that it commenced a tender offer to acquire all of the outstanding shares of common stock of Cypress for $4.25 per share in cash. That offer represented a 70% premium over the $2.50 closing price of Cypress' stock on July 16, 2010, the last trading day before Ramius publicly announced its proposal to acquire the Company for $4.00 per share in cash.  

As of the close of business on December 9, 2010, approximately 2,993,774 shares of Common Stock of Cypress, representing approximately 7.8% of all outstanding shares, were validly tendered and not withdrawn pursuant to the tender offer.  This amount does not include the 3,815,000 shares owned by Ramius and its affiliates.

Ramius has also entered into a confidentiality agreement with Cypress to conduct due diligence in connection with its tender offer or a possible negotiated transaction with Cypress.  The confidentiality agreement does not restrict Ramius' ability to continue or consummate its current tender offer or to conduct a proxy solicitation in connection with the Company's 2011 Annual Meeting of Stockholders.

The full text of the letter follows:

Dear Board Members:

Following our conversations with Perella Weinberg Partners over the past few weeks, this letter sets forth the willingness of Ramius V&O Acquisition LLC and its affiliates ("V&O Acquisition") to offer to acquire all of the outstanding common stock (the "Common Stock") of Cypress Bioscience, Inc. ("Cypress") not already owned by V&O Acquisition and its affiliates in a negotiated tra
'/>"/>

SOURCE Ramius LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cypress Denies Ramius Legal Right to Stockholder List Materials
2. UC San Diego Offers New Certificate for Clinical Trials Administration in Latin America
3. U of C scientist offers better ways to engineer Earths climate to prevent dangerous global warming
4. Emerson Ecologics Exclusively Offers EcoNugenics ProstaCaid
5. New paper offers breakthrough on blinking molecules phenomenon
6. Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome
7. Research from Rensselaer Polytechnic Institute professor offers clues to Alzheimers disease
8. Carl Zeiss Offers Online Promotions – Discounts on Stereomicroscopy and Converting to 3D Imaging
9. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
10. Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists
11. Michael Youssef Offers Insight into the Muslim Perspective on Oil and the World Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... the right people at the table for significant business ... achieving clinical and operational goals. The 22 nd ... 2014, in San Diego , featured ... discussing how partnerships have positively impacted their objectives. ... Officer of Cape Regional Medical Center located in ...
(Date:7/23/2014)... , July 23, 2014 ... portfolio company of Trendlines Agtech , announced ... Israel,s leading agricultural thermoplastics ... Valentis,s technology combines nanocrystalline cellulose (NCC), ... waste, with additional nanoparticles to produce highly improved ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2
... - YM BioSciences Inc. (NYSE Alternext US:YMI, ... develops and commercializes differentiated products for patients ... clearance from Canadian regulatory authorities to initiate ... nimotuzumab, its EGFR-targeting antibody, in combination with ...
... Start of Q4 2008 , - Evaluation of strategic alternatives ... RoleSAN DIEGO, Jan. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext ... reduction-in-force in an effort to extend its remaining cash and ... a reduction implemented in October 2008. In all, the ...
... Jan. 5 LightLab Imaging Inc. today,announced ... past year that are,the culmination of sustained ... These advances significantly increase the Company,s leadership,position ... OCT is a new,high-resolution, high-speed imaging ...
Cached Biology Technology:YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3ADVENTRX Announces Further Cost-Cutting Measures 4ADVENTRX Announces Further Cost-Cutting Measures 5LightLab Imaging Leads Global Advancement of Intracoronary Imaging 2LightLab Imaging Leads Global Advancement of Intracoronary Imaging 3
(Date:7/23/2014)... drought that has the entire country in its grip is ... also be responsible for the proliferation of a heat-loving amoeba ... and hot springs, which the drought has made warmer than ... of an infection caused by this parasite after swimming in ... nose of an individual and travels to the brain. Nose ...
(Date:7/23/2014)... The Worldwide Innovative Networking in personalized cancer medicine, ... Cancer Center at Thomas Jefferson University will ... only member of this prestigious group in the Tri-State ... delivery of innovative personalized medicine to the patient by ... advocacy. , "Our participation in the WIN consortium means ...
(Date:7/23/2014)... play an increasingly important role in carbon and nutrient ... expand, according to research published this week in the ... , University of British Columbia researchers plumbed the depth ... chart how microbial community metabolism changes as oxygen minimum ... picture of how SUP05 a bacterial group related ...
Breaking Biology News(10 mins):Diseases of another kind 2New partnership brings more personalized cancer treatment to Philadelphia 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... New Rochelle, NY, September 9, 2010A subset of ... associated with more illness and greater allergic hypersensitivity, ... Blood, and Lung Institute,s Severe Asthma Research Program ... Pediatric Allergy, Immunology, and Pulmonology , a ...
... The National Institutes of Health is launching two major ... curtail the nation,s childhood obesity epidemic. One will ... and the other will examine community efforts to reduce ... public health concern. If we don,t curb this widespread ...
... USDA Agriculture and Food Research Initiative (AFRI) grant will help ... gene system of sorghum will lead to enhanced bioenergy production ... we already know about and tailoring them to bioenergy uses ... professor of crop sciences and member of the Energy Biosciences ...
Cached Biology News:Research and insights on severe asthma in children 2NIH-funded studies aim to prevent, treat childhood obesity 2NIH-funded studies aim to prevent, treat childhood obesity 3U of I receives $1 million USDA grant to study Glossy15 in sorghum 2
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
RECK (F-20)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: